These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 25897262)

  • 1. Clinical features, epidemiology, and therapy of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    Clin Epidemiol; 2015; 7():249-57. PubMed ID: 25897262
    [TBL] [Abstract][Full Text] [Related]  

  • 2. EPIDEMIOLOGY, PATHOGENESIS and DIAGNOSIS of LYMPHANGIOLEIOMYOMATOSIS.
    Taveira-DaSilva AM; Moss J
    Expert Opin Orphan Drugs; 2016; 4(4):369-378. PubMed ID: 27833825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical and molecular insights into lymphangioleiomyomatosis.
    Steagall WK; Taveira-DaSilva AM; Moss J
    Sarcoidosis Vasc Diffuse Lung Dis; 2005 Dec; 22 Suppl 1():S49-66. PubMed ID: 16457017
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The natural history of lymphangioleiomyomatosis: markers of severity, rate of progression and prognosis.
    Taveira-DaSilva AM; Pacheco-Rodriguez G; Moss J
    Lymphat Res Biol; 2010 Mar; 8(1):9-19. PubMed ID: 20235883
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Moss J
    F1000Prime Rep; 2014; 6():116. PubMed ID: 25580270
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MicroRNA-21 is induced by rapamycin in a model of tuberous sclerosis (TSC) and lymphangioleiomyomatosis (LAM).
    Trindade AJ; Medvetz DA; Neuman NA; Myachina F; Yu J; Priolo C; Henske EP
    PLoS One; 2013; 8(3):e60014. PubMed ID: 23555865
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sirolimus decreases circulating lymphangioleiomyomatosis cells in patients with lymphangioleiomyomatosis.
    Cai X; Pacheco-Rodriguez G; Haughey M; Samsel L; Xu S; Wu HP; McCoy JP; Stylianou M; Darling TN; Moss J
    Chest; 2014 Jan; 145(1):108-112. PubMed ID: 24051985
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Changes in lung function and chylous effusions in patients with lymphangioleiomyomatosis treated with sirolimus.
    Taveira-DaSilva AM; Hathaway O; Stylianou M; Moss J
    Ann Intern Med; 2011 Jun; 154(12):797-805, W-292-3. PubMed ID: 21690594
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
    Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
    Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
    Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
    PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
    Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
    Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of beta-agonists on LAM progression and treatment.
    Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J
    Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lymphangioleiomyomatosis.
    Taveira-DaSilva AM; Steagall WK; Moss J
    Cancer Control; 2006 Oct; 13(4):276-85. PubMed ID: 17075565
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy for Lymphangioleiomyomatosis and Tuberous Sclerosis: Progress and Future Directions.
    Liu HJ; Krymskaya VP; Henske EP
    Chest; 2019 Dec; 156(6):1062-1067. PubMed ID: 31437431
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus treatment of abdominal lymphangioleiomyoma in five women with sporadic lymphangioleiomyomatosis.
    Mohammadieh AM; Bowler SD; Silverstone EJ; Glanville AR; Yates DH
    Med J Aust; 2013 Jul; 199(2):121-3. PubMed ID: 23879512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Smooth muscle-like cells in pulmonary lymphangioleiomyomatosis.
    Krymskaya VP
    Proc Am Thorac Soc; 2008 Jan; 5(1):119-26. PubMed ID: 18094094
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lymphangioleiomyomatosis: Current understanding and potential treatments.
    Moir LM
    Pharmacol Ther; 2016 Feb; 158():114-24. PubMed ID: 26713679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lymphangioleiomyomatosis and tuberous sclerosis complex.
    Chorianopoulos D; Stratakos G
    Lung; 2008; 186(4):197-207. PubMed ID: 18408969
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Pulmonary lymphangioleiomyomatosis: From pathogenesis to management].
    Chebib N; Khouatra C; Lazor R; Archer F; Leroux C; Gamondes D; Thivolet-Bejui F; Cordier JF; Cottin V
    Rev Mal Respir; 2016 Oct; 33(8):718-734. PubMed ID: 26604019
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of chemokines in migration of metastatic-like lymphangioleiomyomatosis cells.
    Pacheco-Rodriguez G; Moss J
    Crit Rev Immunol; 2010; 30(4):387-94. PubMed ID: 20666708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.